Kura Oncology to Report Third Quarter 2021 Financial Results
28 oct. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
18 oct. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
07 sept. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2021 Financial Results
05 août 2021 16h05 HE
|
Kura Oncology, Inc.
– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
04 août 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Second Quarter 2021 Financial Results
29 juil. 2021 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
29 juil. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
24 juin 2021 08h30 HE
|
Kura Oncology, Inc.
– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
10 juin 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Carol Schafer to Board of Directors
04 juin 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...